347 results about "Natural killer cell" patented technology

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and / or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.

Provided are a method and system for enriching natural killer (NK) cells in a blood sample.

The invention belongs to the field of chemical medicines, and particularly relates to a combined medicine for preventing and / or treating prostatic cancer, application of the combined medicine and a medicine composition. The combined medicine disclosed by the invention comprises immune cells with enhanced infiltration degree and a galectin-1 inhibitor; the immune cells with enhanced infiltration degree are natural killer (NK) cells with TTTY15-USP9Y chimera RNA knocked out, the infiltration degree and anti-tumor activity of the NK cells in a prostate cancer microenvironment can be improved, and the activated NK cells have a stronger killing effect on tumor cells in vitro. The immune cells with enhanced infiltration degree and the galectin-1 inhibitor are combined for use, so that the composition shows a synergistic effect in treatment of prostatic cancer, and has a wide application prospect.

A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.

Provided herein is a method for treating Parkinson's disease (PD). The method can include identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating PD.

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

The present disclosure provides a method for preparing natural killer (NK) cells with increased secretion of cytokines and increased cytotoxicity. The present invention uses IL-12 during transfection to generate CAR-NK cells with increased functional activities (cytotoxicity and secretion of cytokines) against tumor cells.

The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.

Methods are provided for reprogramming M2-like macrophages to M1-like macrophages, which reverses the proinflammatory to anti-inflammatory shift observed during the course of certain cancers, co-administered with one or more types of engineered cells such as, without limitation, CAR T-cells, engineered natural killer cells, engineered stem cells or the like. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and / or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for cancers.

Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and / or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.

The invention relates to the technical field of novel biological nanomaterials, in particular to a lung-targeted exosome complex as well as a preparation method and application thereof. The lung targeting type exosome complex is prepared from an NK cell exosome, lipid nanoparticles and an entrapped anti-tumor nucleic acid drug, the NK cell exosome is obtained by extracting a natural killer cell NK-92MI of a human malignant non-Hodgkin lymphoma patient through a differential centrifugation method. The anti-tumor nucleic acid drug is a specific nucleic acid drug targeting a key canceration driving gene in non-small cell lung cancer. The lung targeting type exosome complex prepared by the invention is an excellent and stable drug delivery carrier, has a good lung tissue targeting function, enhances the tumor targeting effect of the exosome, also exerts the tumor cell killing function of the exosome, and has important significance for the treatment of non-small cell lung cancer.

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

Provided herein are methods for pre-activating and expanding an isolated population of NK cells. Further provided herein are methods for the treatment of cancer by administering the pre-activated and expanded NK cells.

The present invention relates to combination therapies for modulating the tumor microenvironment and enhancing infiltration of immune cells into the tumor microenvironment with a bispecific anti-EGFR / c-Met antibody in combination with a PD-(L) 1 axis inhibitor. The invention also relates to combination therapies for inhibiting EGFR and MET signaling pathways in tumor cells, and targeting tumor cells expressing EGFR and MET to be disrupted by immune effector cells such as natural killer cells and macrophages by antibody dependent cytotoxicity (ADCC) and cell gnawing mechanisms, respectively.

Provided herein are compositions of NK-92® cells that express a CD19 CAR, CD16 and IL2, and the method of using these cells to and treat cancer in a patient.

The present invention relates to a composition for enhancing immunity, containing, as an active ingredient, a polysaccharide enzyme-treated product derived from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified polysaccharide fraction thereof. The composition for enhancing immunity according to the present invention, comprising the polysaccharide enzyme-treated product of the mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora or the novel purified polysaccharide fraction thereof, is composed of specific types and contents of sugars and significantly increases the activity of macrophages, splenocytes, and NK cells upon application thereto, thereby being applicable as an immunopotentiator or a composition for enhancing immunity.

This invention provides engineered natural killer (NK) cells and methods for producing engineered NK cells. [Solution] The present invention provides engineered natural killer (NK) cells, which are genetically modified to reduce the expression, activity, and / or signaling of the FcRγ chain in the cells. The engineered NK cells and compositions comprising the engineered NK cells are useful for treating diseases such as cancer.

Provided herein are methods for producing an isolated population of prepared NK cells. In particular embodiments, prepared NK cells are expanded for a certain duration of time. In particular embodiments, prepared NK cells are expanded in one or more certain media(s). Further provided herein are compositions for preparing NK cells, compositions comprising prepared NK cells, and methods for the treatment of disease by administering the prepared NK cells.

The present application relates to single-domain antibodies and constructs comprising the single-domain antibodies, both of which exhibit affinity and specificity toward the CD16a activating receptor on natural killer cells and antigens on cancer cells, bacteria, parasites, or viruses.

This disclosure provides compositions and combinations for treating cancer. The compositions or combinations comprise a plant virus and a natural killer (NK) cell agonist.

The invention discloses a preparation method of a silicon dioxide nano vaccine for mediating constant natural killer T (iNKT) cells and application of the silicon dioxide nano vaccine in the field of tumor immunotherapy. The iNKT cell is a special T cell subset which can be activated by a glycolipid antigen presented by CD1d, and can directly kill tumor cells and activate other immune cells. Clinically, the classical agonist alpha GC of the iNKT cell can lead to function depletion of the iNKT cell after multiple intravenous administration, and finally evolves into an inactive state. Although the CD1d / alpha GC protein complex relieves the iNKT cell anenergetic state to a certain extent, the CD1d / alpha GC protein complex is easily degraded and cleared in a complex physiological environment, and the treatment effect is weakened. The characteristics of large aperture and high specific surface area of dendritic mesoporous silica are utilized, CD1d / alpha GC is loaded into a pore channel of a mesoporous nano-material, and the design can protect protein drugs from being degraded in blood circulation, so that a nano-vaccine capable of effectively mediating iNKT cells and successfully relieving the inability of the iNKT cells is constructed; and the effectiveness of the compound in tumor treatment is verified. The patent is supported by the national natural science fund (82001958).

The present invention relates to an expansion culture method for natural killer cells and, more particularly, to an expansion culture method for natural killer cells, wherein the cultured natural killer cells are treated with an HDAC inhibitor. According to the present invention, when natural killer cells are subjected to in vitro expansion culture, the cells can be restrained from undergoing cell death, resulting in a remarkable improvement in the viability and production yield of the cells. Thus, natural killer cells, which are needed for cell therapy, such as cancer therapy, etc., can be obtained effectively.

To provide: natural killer cells with increased anti-cancer activity; cell therapeutic agents or pharmaceutical compositions containing the natural killer cells or a population thereof as an active ingredient; and methods for treating cancer.SOLUTION: The present invention relates to a natural killer cell with increased anti-cancer activity and to immunotherapeutic uses thereof, the natural killer cell according to one aspect having the increased relative MFI of a significant specific receptor against cancers including glioblastoma and having the effect of enabling effective anti-cancer immunotherapy.SELECTED DRAWING: Figure 9

The invention belongs to the technical field of tumor immunotherapy, and relates to an anti-Claudin18.2 single-domain antibody, a multifunctional fusion protein, a recombinant natural killer cell (CT-CAR-NK), and preparation and application thereof. Through alpaca immunization and phage display library construction and panning, the single-domain antibody VHH-C18.2-1 specifically combined with Claudin18.2 is obtained, and the amino acid sequence of the single-domain antibody VHH-C18.2-1 is SEQ ID NO: 1. The amino acid sequence of the designed fusion protein is SEQ ID NO: 3, the fusion protein sequentially comprises a VHH-C18.2-1, a flexible Linker, a TGF-beta RII extracellular domain, a CD8alpha hinge region, a CD8alpha transmembrane region, a 4-1BB intracellular domain and a CD3zeta intracellular domain from the N end to the C end, and the fusion protein has the functions of targeting, resisting TGF-beta inhibition and activating signals. The fusion protein gene transfects human peripheral blood CD56 + CD3-NK cells through lentivirus to obtain CT-CAR-NK, in-vitro verification shows that the CT-CAR-NK still keeps efficient killing in an immunosuppression environment, tumor growth can be remarkably inhibited in vivo, the lifetime can be prolonged, and a safe and efficient scheme is provided for Claudin18.2 positive solid tumor treatment.

The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and / or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and / or CD19, methods of making a cell comprising the same and vectors encoding the same.

We provide compositions and methods to enhance the anti-cancer specificity of chimeric antigen receptor natural killer cells (CAR-NK) by activating them against cancer antigens while inhibiting them against human leukocyte antigen DR (HLA-DR). HLA-DR is reportedly lost or downregulated in a substantial proportion of hematologic malignancies. An anti-HLA-DR inhibitory CAR (iCAR) is provided to effectively suppress NK cell activation against HLA-DR-expressing cells. Dual CAR-NK cells, which co-express the anti-CD19 or anti-CD33 activating CAR and the anti-HLA-DR iCAR, can preferentially target HLA-DR-negative cells over HLA-DR-positive cells in vitro. The HLA-DR-mediated inhibition is positively correlated with both iCAR and HLA-DR densities. Surrounding cells that express HLA-DR do not affect the target selectivity of the dual CAR-NK cells. We have confirmed that HLA-DR-positive cells are resistant to dual CAR-NK cell-mediated killing in a xenograft mouse model. This can be used for enhancing CAR-NK and CAR-T cell specificity against malignancies with HLA-DR loss.

The invention belongs to the field of biomedicine, and particularly relates to a detection method, an evaluation method and application of umbilical cord blood-derived natural killer cells. The detection method disclosed by the invention is used for carrying out related detection and data analysis on the natural killer cells from umbilical cord blood, is high in pertinence and can be used as a detection method for delivering the NK cells from a warehouse. According to the evaluation method, the relationship between the NK function related protein and the cell killing ability is determined, the killing ability of the NK cells is judged by detecting functional protein indexes CD3, NKG2A, CD56, CD16, NKP46 and CD107A of the natural killer cells and calculating NK scores of samples based on detection results, the sensitivity and specificity are high, and the method can be used for evaluating the killing ability of the NK cells.

The invention discloses an engineered exosome preparation with tumor targeting and specific gripper response release functions as well as a preparation method and application of the engineered exosome preparation. The preparation comprises a myocardial cell exosome, an NK cell biotinylation activation antibody, a tumor disease biotinylation antibody, streptavidin, a tumor fiber matrix FAP targeting peptide and a tumor matrix enzyme response peptide, and anchoring is carried out through an acetamide compound-polyethylene glycol anchor point platform. The engineering bispecific exosome preparation with good tumor targeting and barrier breakthrough ability and immune cell activation effect is prepared, and the preparation breaks a solid tumor compact fiber barrier and increases NK cell infiltration by utilizing the fibrosis treatment ability of the myocardial cell exosome and the capture and targeting effects of an anchor point platform; the natural killer cells are in close contact with tumor cells, the lasting tumor cell killing effect is achieved, and the tumor matrix environment is fundamentally changed.

Provided for herein in several embodiments are anti-BCMA binding moieties. These anti-BCMA binding moieties may be used in BCMA-directed chimeric antigen receptors (CARs). Also disclosed herein are immune cell-based compositions comprising the anti-BCMA binding moieties and BCMA-directed CARs. In several embodiments, the immune-cell based compositions also target an additional tumor marker and / or an additional epitope of BCMA. In several embodiments, the BCMA-directed CAR is expressed in a Natural Killer cell. In several embodiments, combinations of BCMA-CAR-expressing NK cells are administered in conjunction with, for example CAR-expressing NK cells and / or CAR-expressing T cells that are directed to an additional cancer marker and / or an additional epitope of BCMA. Also provided for herein are methods and uses of the chimeric antigen receptors in immunotherapy.